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ABSTRACT 
Low circulating 25-hydroxyvitamin D (25OHD) levels are a risk factor for acute respiratory infection 
(e.g., bronchiolitis) in children. However, little is known about the relation of circulating 25OHD with 
the many downstream functional molecules in target organs – such as the airway – and with clinical 
outcomes. In this prospective multicenter study of infants (age <1 year) hospitalized with 
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bronchiolitis, we measured serum 25OHD levels and profiled the metabolome of 144 nasopharyngeal 
airway samples. Among 254 metabolites identified, we defined a set of 20 metabolites that are related 
to lower serum 25OHD and higher vitamin D-binding protein levels. Of these metabolites, 9 
metabolites were associated with a significantly higher risk of positive pressure ventilation use. These 
metabolites were glycerophosphocholines esterified with proinflammatory fatty acids (palmitate, 
arachidonate, linoleate, and stearate), sphingomyelins, alpha-hydroxyisovalerate, 2-hydroxybutyrate, 
and 3-(4-hydroxyphenyl)lactate (all FDR<0.05). Based on the multicenter data, vitamin D-related 
airway metabolites were associated with risks of bronchiolitis severity.  
 
BACKGROUND 
 Bronchiolitis is a common acute respiratory infection (ARI) and the leading cause of 
hospitalizations in U.S. infants.
1
 Previous studies have investigated the role of vitamin D in 
bronchiolitis pathobiology because of its immune-modulating properties and likely role in lung 
development.
2
 Indeed, 25-hydroxyvitamin D (25OHD) undergoes enzymatic conversion to its 
functionally-active form (1,25-dihydroxyvitamin D [1,25OH2D]) in immune cells and epithelium 
cells.
2
 Epidemiological studies have demonstrated associations of lower circulating 25OHD levels at 
birth or during infancy with higher risks of ARI, including bronchiolitis.
3-5
 Additionally, recent 
individual participant data meta-analysis of 25 randomized controlled trials also showed protective 
effects of vitamin D supplementation against ARI among individuals with low baseline 25OHD 
levels.
6  Most of these studies have assessed the concentration of blood 25OHD directly in relation to 
disease processes.
3-7
 However, little is known about relationships of circulating vitamin D compounds 
with the many downstream functional molecules in target organs – such as the airway – and with 
clinical outcomes. Metabolomics addresses this knowledge gap by systematically measuring all 
metabolites, which represent the downstream functional products of an individual’s genetic make-up 
and environmental exposures, such as vitamin D status.
8
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 In this context, by examining the nasopharyngeal airway metabolomic profiles from a nested 
subset of prospective cohort of infants with bronchiolitis, we aimed to examine the interrelationships 
between serum vitamin D-related compounds (25OHDs and vitamin D-binding protein [DBP]), 
airway metabolome, and disease severity. Specifically, we hypothesized that vitamin D-related airway 
metabolites are associated with higher risks of positive pressure ventilation (PPV) use. 
 
METHODS 
 We analyzed the data from a multicenter prospective cohort study of infants 
hospitalized with bronchiolitis (severe bronchiolitis). Details of the study design, setting, 
participants, data measurement, and analysis may be found in the Online Supplement 
(Supplemental Methods). Briefly, this cohort study, the 35th Multicenter Airway Research 
Collaboration (MARC-35),
9,10
 enrolled 1,016 infants (aged <12 months) hospitalized for 
bronchiolitis at 17 sites across 14 U.S. states (Table E1) during the 2011–2014 winter 
seasons. Bronchiolitis was defined by the American Academy of Pediatrics guidelines.
11
 The 
institutional review board of each participating hospital approved the study. Written informed 
consent was obtained from the infant’s parent or guardian. 
 In addition to the measurements of phenotypic data through structured interview and 
medical record review, we collected blood and nasopharyngeal airway samples within 24 
hours of hospitalization using a standardized protocol.
9,10
 Serum total 25OHD and DBP 
levels were quantified by immunoassays; serum free and bioavailable 25OHD levels were 
computed using previously-validated formulas.
12
 Respiratory viruses were tested by using 
real-time PCR assays at Baylor College of Medicine (Houston, TX, USA) and 
nasopharyngeal metabolites (metabolome) were profiled using ultra-high performance liquid 
chromatography-tandem mass spectrometry by Metabolon (Durham, NC, USA). The details 
of these testing and their quality control may be found in Supplemental Methods. The 
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primary clinical outcome was the use of PPV – defined as the use of continuous positive 
airway pressure and/or intubation during hospitalization.
10
 
For the current study, we analyzed 144 infants who underwent metabolomic profiling of 
nasopharyngeal airway samples. These 144 infants had sufficient amount of nasopharyngeal airway 
sample for metabolome testing. To identify a subset of nasopharyngeal metabolites related to lower 
levels of circulating 25OHD (free, bioavailable, and total), we used sparse partial least squares (sPLS) 
regression with cross-validation and LASSO penalization minimizing overfitting. Next, to examine 
the associations of these selected nasopharyngeal metabolites with risks of PPV, we fit multivariable 
logistic regression and generalized linear mixed-effects models adjusting for age, sex, race/ethnicity, 
feeding status, weight at presentation, detected virus, free 25OHD level, and potential patient 
clustering within hospitals. P-values were adjusted for multiple comparisons using the Benjamini-
Hochberg false discovery rate (FDR) method. Analyses used R version 3.4.  
 
RESULTS 
 Of 144 infants with bronchiolitis in the analytic cohort, the median age was 3 months (IQR 1-
6 months), 61% were male, and 17% underwent PPV during hospitalization. The median level of 
serum total 25OHD was 23.7 ng/ml (IQR 16.0-31.1 ng/ml) and that of free 25OHD was 10.0 pg/ml 
(IQR 7.5-15.0 pg/ml), with significant correlation between these levels (r=0.66; P<0.001; Figure E1). 
While most patient characteristics were not significantly different by free 25OHD status (Table 1), 
infants with lower free 25OH levels were more likely to be male, non-Hispanic white, and breastfed 
(all P<0.05).  
 Metabolomic profiling of nasopharyngeal airway samples detected a total of 254 metabolites 
from 62 sub-pathways within 8 super-pathways. Based on sPLS ordination, the global metabolomics 
profiles clustered by free 25OHD status (Figure E2). By estimating their loading coefficients in the 
sPLS model, we defined a set of top 20 nasopharyngeal metabolites that are most strongly associated 
with lower serum 25OHD (free, bioavailable, and total) levels, as well as higher DBP levels (Figures 
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1 and E3). These metabolites were products of lipid, amino acid, and carbohydrate metabolism. Of 
these nasopharyngeal metabolites, in the logistic regression models adjusting for potential 
confounders, 13 metabolites were significantly associated with a higher risk of PPV use (all 
FDR<0.05). In the mixed-effects models, 9 metabolites remained significantly associated with a 
higher risk of PPV use (all FDR<0.05) –glycerophosphocholines (GPCs) esterified with palmitate, 
arachidonate, linoleate, and stearate, sphingomyelins, alpha-hydroxyisovalerate, 2-hydroxybutyrate, 
and 3-(4-hydroxyphenyl)lactate (Figure 1). Additionally, the discrimination ability of selected 20 
metabolites on the risk of PPV was high with area-under-the receiver operating characteristic curve of 
0.95 (Figure E4). 
 
DISCUSSION 
 In this multicenter study of infants with severe bronchiolitis, the levels of circulating vitamin 
D-related compounds were associated with differences in the nasopharyngeal airway metabolomic 
profile. Specifically, from a total of 254 detected metabolites, we derived a set of 20 airway 
metabolites – a metabolomic signature – that was associated with lower serum 25OHD (free, 
bioavailable, and total) levels. Of these, 9 airway metabolites (e.g., glycerophospholipids esterified 
with specific fatty acids, sphingolipids) were significantly associated with a higher risk of PPV use. 
To our knowledge, this is the first study that has investigated the interrelations between circulating 
vitamin D-related compounds, airway metabolome, and clinical outcomes in infants with 
bronchiolitis. 
 In agreement with our findings, studies of children
13,14
 and adults
15-18
 with various conditions 
(e.g., asthma, sepsis) have reported the relationship of lower 25OHD levels with unique blood and 
urine metabolomic profiles, particularly in lipids – a major component of cell membrane and 
molecular signaling.
8
 For example, a nested study of 245 participants in a clinical trial reported that 
children exposed to lower in utero 25OHD levels had higher serum concentration of palmitate, 
stearate, linoleate, and arachidonate at age 3 years.
13
 Cohort studies of adults in Germany and Finland 
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also demonstrated inverse associations between serum 25OHD levels and these fatty acids.
15,16
 
Palmitate and stearate are saturated fatty acids known to enhance inflammatory signaling.
13
 Higher 
consumption of these saturated fats is linked to dyslipidemia, which is associated with allergic 
sensitization, airway obstruction, and childhood asthma.
19
 Additionally, linoleate and arachidonate (ω-
6 polyunsaturated fatty acids) are precursor of the arachidonic cascade that produces lipid mediators 
(e.g., leukotrienes, prostaglandins) and plays a major role in airway inflammation.
8
 Furthermore, 
emerging evidence has also shown that 1,25OH2D modulates metabolism of sphingolipids – signaling 
molecules involved in immune response and inflammation, which are related to airway diseases, 
including bronchiolitis
10
 and asthma.
8
   
 In addition to these proinflammatory lipids, in agreement with our data, cross-sectional 
studies also reported associations of alpha-hydroxyisovalerate – a branched-chain amino acid – in 
urine with respiratory syncytial virus ARI in children
14
 and asthma in adults.
17
 Furthermore, a cross-
sectional study of adult patients with sepsis also found relations of low 25OHD and high 2-
hydroxybutyrate – an organic acid – levels in the serum with higher mortality.18 Our study is 
consistent with these prior studies showing 25OHD-metabolome (in blood or urine) associations, and 
extends them by demonstrating the interrelations of circulating 25OHD, metabolome in the airway 
(the disease locus), and bronchiolitis severity in infants. 
 The current study has several potential limitations. First, the study was based on the 
nasopharyngeal samples that were measured <24 hours of hospitalization at a single time-point. 
Second, as with any observational study, the observed associations do not necessarily prove causality, 
and might be explained by reverse causation and unmeasured confounders (e.g., between-hospital 
difference in intensive care use). However, we statistically accounted for hospital-level effects. Third, 
it is possible that environmental exposures (e.g., medical management, diet) could have influenced the 
airway metabolome. Yet, given the long half-life of serum 25OHD and cell membrane lipids,
20
 this 
factor was unlikely to have affected 25OHD status or confounded the observed associations of 
25OHD with metabolome, particularly with cell membrane lipids. Fourth, our study did not include 
data from a “control” group. Regardless, the study objective was not to assess the relationship of 
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circulating 25OHD, airway metabolome, and the development of bronchiolitis (yes/no), but to 
determine their contributions to the disease severity among infants with bronchiolitis. Fifth, although 
we used statistical methods to minimize over-fitting, external validations in an independent population 
and mechanistic evaluations in experimental model systems are necessary to confirm our 
observations. Sixth, while an integration of other omics (e.g., genetics), environmental, and clinical 
data to systematically endotype bronchiolitis was out of the scope in the current study, it is an 
important area for examination in future work. Lastly, even with our multicenter design and 
racially/ethnically-diverse patient population, we must generalize our inferences cautiously beyond 
infants hospitalized with bronchiolitis.  
 In conclusion, these multicenter data of infants with bronchiolitis demonstrated that lower 
levels of serum vitamin D-related compounds were associated with a set of nasopharyngeal airway 
metabolites – a metabolomic signature. Of these, specific metabolites (e.g., glycerophospholipids 
esterified with proinflammatory fatty acids, sphingolipids) were significantly associated with a higher 
risk of PPV use. While causal inference remains premature, our data – in conjunction with prior 
studies – suggest that circulating 25OHD influences the airway metabolites related to inflammatory 
pathways, thereby contributing to disease severity. Our findings should facilitate further investigations 
into the complex interplay between the environmental exposures (e.g., vitamin D supplementation), 
host immune response in the airway, and bronchiolitis pathobiology. 
 
ACKNOWLEDGMENT 
 We thank the MARC-35 study hospitals and research personnel for their ongoing dedication 
to bronchiolitis and asthma research (Table E1 in the Online Supplement). We also thank Janice A. 
Espinola, MPH, and Ashley F. Sullivan, MS, MPH (Massachusetts General Hospital, Boston, MA), as 
well as Alkis Togias, MD (National Institute of Allergy and Infectious Diseases) for their 
contributions to the study.  
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
REFERENCES 
1. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA, Jr. Trends in bronchiolitis 
hospitalizations in the United States, 2000-2009. Pediatrics. 2013;132(1):28-36. 
2. Camargo Jr CA. Vitamin D, acute respiratory infections, and asthma/COPD. In: Feldman D, 
Pike W, Bouillon R, Giovannucci E, Goltzman D, Hewison M, eds. Vitamin D. Fourth 
edition. Cambridge, Massachusetts: Elsevier Academic Press; 2017. 
3. Camargo CA, Jr., Ingham T, Wickens K, et al. Cord-blood 25-hydroxyvitamin D levels and 
risk of respiratory infection, wheezing, and asthma. Pediatrics. 2011;127(1):e180-187. 
4. Esposito S, Lelii M. Vitamin D and respiratory tract infections in childhood. BMC Infect Dis. 
2015;15:487. 
5. Hollams EM, Teo SM, Kusel M, et al. Vitamin D over the first decade and susceptibility to 
childhood allergy and asthma. J Allergy Clin Immunol. 2017;139(2):472-481 e479. 
6. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute 
respiratory tract infections: systematic review and meta-analysis of individual participant 
data. BMJ. 2017;356:i6583. 
7. Mansbach JM, Piedra PA, Borregaard N, et al. Serum cathelicidin level is associated with 
viral etiology and severity of bronchiolitis. J Allergy Clin Immunol. 2012;130(4):1007-1008 
e1001. 
8. Kelly RS, Dahlin A, McGeachie MJ, et al. Asthma Metabolomics and the Potential for 
Integrative Omics in Research and the Clinic. Chest. 2017;151(2):262-277. 
9. Hasegawa K, Mansbach JM, Ajami NJ, et al. The relationship between nasopharyngeal CCL5 
and microbiota on disease severity among infants with bronchiolitis. Allergy. 2017 [Epub 
ahead of print]. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
10. Stewart CJ, Mansbach JM, Wong MC, et al. Associations of nasopharyngeal metabolome and 
microbiome with severity among infants with bronchiolitis: A multi-omic analysis. Am J 
Respir Crit Care Med. 2017;196(7):882-891. 
11. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, 
management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-1502. 
12. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the vitamin D-
bone mineral density relationship. J Bone Miner Res. 2011;26(7):1609-1616. 
13. Blighe K, Chawes BL, Kelly RS, et al. Vitamin D prenatal programming of childhood 
metabolomics profiles at age 3 y. Am J Clin Nutr. 2017;106(4):1092-1099. 
14. Adamko DJ, Saude E, Bear M, Regush S, Robinson JL. Urine metabolomic profiling of 
children with respiratory tract infections in the emergency department: a pilot study. BMC 
Infect Dis.. 2016;16(1):439. 
15. Nelson SM, Panagiotou OA, Anic GM, et al. Metabolomics analysis of serum 25-hydroxy-
vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J 
Epidemiol. 2016;45(5):1458-1468. 
16. Vogt S, Wahl S, Kettunen J, et al. Characterization of the metabolic profile associated with 
serum 25-hydroxyvitamin D: a cross-sectional analysis in population-based data. Int J 
Epidemiol. 2016;45(5):1469-1481. 
17. Adamko DJ, Nair P, Mayers I, Tsuyuki RT, Regush S, Rowe BH. Metabolomic profiling of 
asthma and chronic obstructive pulmonary disease: A pilot study differentiating diseases. J 
Allergy Clin Immunol. 2015;136(3):571-580 e573. 
18. Lasky-Su J, Dahlin A, Litonjua AA, et al. Metabolome alterations in severe critical illness 
and vitamin D status. Crit Care. 2017;21(1):193. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
19. Vinding RK, Stokholm J, Chawes BLK, Bisgaard H. Blood lipid levels associate with 
childhood asthma, airway obstruction, bronchial hyperresponsiveness, and aeroallergen 
sensitization. J Allergy Clin Immunol. 2016;137(1):68-74 e64. 
20. Thompson Jr GA. The regulation of membrane lipid metabolism. Vol 2: CRC Press; 1992. 
 
FIGURE LEGEND 
Figure 1. Correlations between circulating vitamin D compounds and selected nasopharyngeal 
airway metabolites, and their associations with risks of positive pressure ventilation among 
infants with bronchiolitis 
The heatmap (left) shows the correlations between the circulating vitamin D-related compounds and 
20 selected nasopharyngeal metabolites that were examined using hierarchical clustering with average 
linkage algorithm. The table (right) summarizes the adjusted associations between each of selected 
nasopharyngeal metabolites with risks of PPV use. Bold results are statistically significant with FDR 
of <0.05. OR are calculated per each incremental increase in scaled level. 
Abbreviations: 25OHD, 25-hydroxyvitamin D; CI, confidence interval; DBP, vitamin D-binding 
protein; FDR, false discovery rate; GPC, glycerophosphocholine; OR, odds ratio; sPLS, partial least 
squares. 
* Logistic regression models adjusting for patients’ age, sex, race/ethnicity, feeding status, body 
weight at presentation, detected virus, and serum free 25OHD levels. 
† Generalized linear mixed-effects models adjusting for the covariates above and accounting for 
potential patient clustering within the hospitals.  
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Table 1. Patient Characteristics of Infants Hospitalized for Bronchiolitis by Serum Free 
25-hydroxyvitamin D level 
  Free 25OHD 
<10 pg/ml 
Free 25OHD 
≥10 pg/ml 
P-value 
Variables n=71 n=73   
Characteristics    
Age (mo), median, (IQR) 2 (1-5) 3 (1-6) 0.11 
Male sex 52 (73) 36 (49) 0.006 
Race/ethnicity   0.006 
Non-Hispanic white 39 (55) 31 (43)  
Non-Hispanic black 4 (6) 20 (27)  
Hispanic 23 (32) 18 (25)  
Other 5 (7) 4 (6)  
Parental history of asthma 27 (3) 18 (25) 0.12 
Maternal smoking during pregnancy 6 (9) 6 (8) 0.99 
C-section delivery 26 (37) 25 (35) 0.90 
Prematurity (32-37 weeks) 13 (18) 18 (25) 0.47 
Previous breathing problems before the  
   index hospitalization* 
5 (7) 12 (16) 0.14 
History of eczema 8 (11) 9 (12) 0.99 
Ever attended daycare 10 (14) 13 (18) 0.70 
Sibling in the household    
Mostly breastfed for the first 3 months  
   of age 
45 (64) 27 (39) 0.004 
Smoke exposure at home 5 (7) 11 (15) 0.21 
Corticosteroid use before the index  
   hospitalization 
11 (16) 11 (15) 0.99 
Clinical presentation    
Weight at presentation (kg),  
   median (IQR) 
5.3 (4.4-7.1) 6.3 (4.7-7.8) 0.23 
Respiratory rate at presentation  
   (per minute), median (IQR) 
48 (39-60) 48 (40-59) 0.94 
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Oxygen saturation at presentation   0.81 
<90% 8 (12) 7 (10)  
90%-93% 8 (12) 12 (17)  
≥94% 53 (77) 52 (73)  
Received corticosteroids (systemic or    
  inhaled) during pre-hospitalization visit 
5 (7.0) 6 (8) 0.99 
Virology    
Sole RSV infection 43 (61) 37 (51) 0.31 
Sole rhinovirus infection 12 (17) 14 (19) 0.89 
RSV + rhinovirus coinfection 5 (7) 4 (6) 0.97 
Others 11 (16) 18 (25) 0.25 
Laboratory data    
Serum total 25OHD (ng/ml)†,  
   median (IQR) 
16.7 (8.9-23.7) 29.4 (23.1-34.4) <0.001 
Serum bioavailable25OHD (ng/ml),  
   median (IQR) 
2.4 (1.3-3.0) 4.9 (4.0-7.2) <0.001 
Serum vitamin D-binding protein  
   (μg/ml), median (IQR) 
180.0  
(142.5-241.5) 
132.9  
(85.7-186.0) 
<0.001 
Serum LL-37 (ng/ml), median (IQR) 46.0 (28.0-60.0) 42.0 (30.0-58.0) 0.58 
Food IgE sensitization‡ 7 (10) 11 (15) 0.49 
Aeroallergen IgE sensitization‡ 1 (1) 3 (4) 0.63 
Nasopharyngeal CCL5 (pg/ml), median  
   (IQR) 
38.0  
(18.8-155.2) 
53.9  
(23.7-134.4) 
0.75 
Data are no. (%) of infants unless otherwise indicated. Percentages may not equal 100, because 
of missingness 
Abbreviations: IQR, interquartile range; RSV, respiratory syncytial virus; 25OHD, 25-
hydroxyvitamin D 
* Defined as a child having cough that wakes him/her at night and/or causes emesis, or when the 
child has wheezing or shortness of breath without cough 
† Serum total 25OHD level was significantly associated with the risk of positive pressure 
ventilation (PPV) use (odds ratio per 1 ng/ml increase 0.94; 95%CI 0.89-0.98; P=0.005). In 
addition, younger age (P=0.01) and lower weight at presentation (P=0.007) were also associated 
with a higher risk of PPV use. 
‡ Defined by having one or more positive values for allergen-specific IgE  
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